Viewing a single comment thread. View all comments

Wagamaga OP t1_jd9ype8 wrote

NTNU has been responsible for the basic research. APIM Therapeutics has used the basic research to develop the medicine.

It has taken 18 years and more than EUR 20 million.

The medicine has now been tested on 20 cancer patients who were terminally ill. They had tried all available treatments, and as a last resort they opted to try a new option that was in the experimental stage.

Cancer stopped growing The trials took place in Australia, where there are clinics that specialize in testing new medicines.

The results are very promising and have been published in the journal Oncogene.

Seventy percent of the patients who tested the medicine were stable after six weeks. Twelve continued the medication and were stable for 18 weeks. One woman took the medication for 17 months, and was stable for over two years.

In other words, the cancer stopped growing.

The aim of the testing in Australia was not primarily to check whether the medicine worked, but rather to determine whether it was toxic to humans.

It certainly wasn't toxic.

The medicine has previously been shown to both keep cancer at bay and defeat it in laboratory and animal experiments.

Marit Otterlei is behind all the research. She is a professor of molecular medicine at NTNU


Next-Mobile-9632 t1_jd9zzpl wrote

58% still progressive after 18 weeks, not that great


freshspring_325 t1_jda131q wrote

Unfortunately, that really depends on the cancer type, stage, and treatment history. Progression-free survival for 5 months is actually an improvement for some patient populations.